SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on May 24, 2023 for Raksha Sudhir Valia
Sun Pharma Advanced Research loss widens to Rs 81.99 cr in March quarter
Sun Pharma Advanced Research Company Ltd on Monday said its net loss widened to Rs 81.99 crore in the fourth quarter ended March 2023, impacted by higher expenses. The company had posted a net loss of Rs 71.05 crore in the same period previous fiscal, Sun Pharma Advanced Research Company said in a regulatory filing. Its revenue from operations stood at Rs 47.69 crore compared to Rs 25.24 crore in the year-ago period, it added. The total expenses in the fourth quarter were higher at Rs 140.41 crore against Rs 96.51 crore in the same period a year ago. The company further said that during the quarter, it paused the development of the 'SC0-120' programme due to changing clinical landscape as a result of which it has made provision for committed costs for this programme estimated at Rs 27 crore. For FY23, the company said its net loss stood at Rs 222.58 crore. It was at Rs 203.4 crore in FY23. The revenue from operations in FY23 was Rs 238.78 crore compared to Rs 137.25 crore in FY22 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Press Release relating to Earnings Call for financial results for the fourth quarter and full year ending March 31, 2023. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Board Meeting Intimation for Consideration Of Audited Results For The Year Ended March 31, 2023.
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2023 ,inter alia, to consider and approve 1. To approve Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2023. 2. To consider and recommend final dividend, if any, on the equity shares of the Company for the financial year ended March 31, 2023.
Sun Pharma recalls over 24K pre-filled syringes of generic medication in US
Drug major Sun Pharmaceutical Industries is recalling pre-filled syringes of a drug, used to treat infertility in women, in the US market due to a manufacturing issue, according to the US health regulator. In its latest Enforcement Report, the US Food and Drug Administration (USFDA) noted that the Mumbai-based drug major is recalling 24,194 prefilled syringes of Fyremadel (ganirelix acetate) injection. The company is recalling the affected lot due to the presence of particulate matter, the USFDA said. "A piece of glass was found in a prefilled syringe," it added. The product was manufactured by Sun Pharma and distributed in the US market by New Jersey-based Ferring Pharmaceuticals Inc. The company initiated the countrywide (US) recall on April 19 this year, USFDA stated. The New Jersey-based Sun Pharmaceutical Inc, a unit of the company, has already announced the recall of 16,450 vials of Norepinephrine Bitartrate Injection for "failed impurities/degradation specifications". As p SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39 (3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 USFDA puts on hold Sun Pharma trials on dermatological drug regimen
The US health regulator has directed Sun Pharma to stop trials of a dermatological drug with a 12 mg dose regimen as its usage could lead to blood clots. The drug major on Tuesday said it had a teleconference call with the US Food and Drug Administration (USFDA) regarding a pulmonary embolism (serious adverse events) occurring at the 12 mg dose in one of the long-term Open Label Extension (OLE) studies. As a result, the agency has placed the investigational new drug (IND) on partial clinical hold due to the potential for thrombotic events and is requiring that subjects currently on the 12 mg dose in the OLE studies discontinue that dose, it added. There have been no thrombotic events reported to date for the 8 mg dose and USFDA has not placed the 8 mg dose on hold, the drugmaker said in a regulatory filing. "We are taking immediate steps to transition the patients in the OLE studies to the 8 mg BID dose arm in the ongoing studies," Sun Pharmaceutical Industries stated. No... SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Deuruxolitinib (CTP-543) Clinical Program Update
Attaching the document for your information and dissemination.